The market has been estimated at USD XX billion in 2016 and is projected to reach USD XX billion by the end of 2022, at a CAGR of X% during the forecast period from 2016 to 2022.
Swine disease outbreaks in the US and Europe are starting to reshape the global market. The estimated pig population in 2010 was 966 million, and with countries like China boosting production, this number is set to rise rapidly in the years to come. Although pork consumption in the US has reduced, the rising demand from emerging economies like China more than makes up for the loss in consumption. Even on the supply side, China has created opportunities for smallholder farmers to produce protein sources to meet domestic demand, bolstering swine rearing in the country.
The market is driven by increased pig breeding, domestic and export demand for pork and increasing sow utilization rates.Swine diseases and increase in chicken production are the major factors restraining the market and deflating market pricing for pork production.
The global swine healthcare market has been segmented by diseases: diseases caused by bacteria, mycoplasmas, and spirochetes, domestic viral diseases, parasitic diseases, nutritional deficiencies, toxicoses and poisonings, exotic viral diseases, skin diseases and others; and by swine health products: vaccines, parasiticides, anti-infectives, medicinal feed additives and others.
The global swine healthcare market has also been geographically segmented into Asia-Pacific, Europe, Middle East and North Africa (MENA), North America and Rest of the World, with Asia-Pacific dominating the global market. North America is also an emerging market which has a scope for growth and can potentially dominate the market in the future.
Some of the key players in the market are:
Key Deliverables in the Study